 |
Allogeneic T-cells cultured with anti-CD3 and IL-2; transduced with retroviral vector (SFCMM-3), expressing herpes simplex 1 virus-thymidine kinase (HSV-TK) and truncated low affinity nerve growth factor receptor; selected with anti-low affinity nerve gro |
|---|---|
| Trade Name | |
| Orphan Indication | Immunotherapy for acceleration of T-cell reconstitution in patients undergoing allogeneic hematopoietic stem cell transplantation |
| USA Market Approval | USA |
| USA Designation Date | 2005-01-28 00:00:00 |
| Sponsor | MolMed S.p.A.;Via Olgettina 58;Milan |
